Ronald T. Ackermann, MD, MPH

Among adults with type 2 diabetes who started noninsulin second-line therapy, most modified treatment within 1 year. Discontinuation was by far the most common modification.

Adults with type 2 diabetes who received nonsulfonylurea medications had relative increases in total costs. Receiving newer medication classes led to relatively decreased medical costs.

Evaluation of healthcare utilization and costs over 3 years for adults with insulin-requiring diabetes who transition from multiple daily insulin injections to insulin infusion pumps.

Over 10 years, among adherent participants, lifestyle intervention and metformin were effective and cost-effective for diabetes prevention compared with placebo.